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ABSTRACT
Introduction: Specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non-
small cell lung cancer (NSCLC) patients that may be highly responsive to receptor inhibitor therapy. 18F-FDG PET/CT 
scans can map the glucose metabolism and treatment response of NSCLC. Therefore, we aimed to assess the pattern 
of metabolic response and outcome of inoperable NSCLC treated with epidermal growth factor receptor (EGFR) 
inhibitors, using 18F-FDG PET/CT scan. Methods: A retrospective study of inoperable NSCLC patients on EGFR 
inhibitor treatment that were referred for wholebody18F-FDG PET/CT scans was conducted based on cases scanned 
from January 2011 to June 2014. Comparison was made among serial attenuation-corrected fused PET/CT images for 
all study patients throughout the course of their treatment. Comparison based on PERCIST criteria was categorized 
into 4 levels ie. complete response (CMR), partial response (PMR), stable disease (SMD), progressive metabolic 
disease (PMD). Results: Overall, there were 5 patients identified, mean age: 57.4 years old +/- 2.9 years; The median 
survival time from initiation of EGFR inhibitor treatment to death was 17 months.  Two patients showed initial partial 
metabolic response (PMR), two had progressive metabolic disease (PMD) and one had complete metabolic response 
(CMR) after the initiation of treatment. The patient with initial CMR had relapse and PMD 5 months later. Majority of 
patients eventually succumbed to their illness. Conclusions: Wholebody18F-FDG PET/CT is able to assess metabolic 
treatment response of NSCLC towards EGFR inhibitor treatment. 
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INTRODUCTION
Non-small cell lung cancer (NSCLC) constitutes nearly 
85% of lung cancers, whereby adenocarcinomas 
account for the majority of cases (1). Strategic planning 
for commencement of cytotoxic therapy is required once 
the diagnosis of advanced adenocarcinoma is made. 
This necessitates advanced molecular testing to detect 
anaplastic lymphoma kinase (ALK) rearrangements and 
epidermal growth factor receptor (EGFR) mutations 
which help to prognosticate the likelihood of tumuor 
responsiveness to a certain targeted therapy (2). 
Epidermal growth factor receptor (EGFR) is cell surface 
protein that binds to epidermal growth factor, which 
then acts as a docking site to propagate the receptor to 
become dimerised and leads to autophosphorylation 
of tyrosine and stimulates cell proliferation. This also 
plays a role in cell survival by regulating intracellular 
downstream pathways(3). 
Mutations in the gene that encodes the EGFR protein 
leads to lung cancer. Therefore, development of 
targeted therapy drugs that inhibit this receptor can 
hinder dysregulated cell proliferation, thus control 
disease progression. Targeted therapy utilizes drugs that 
are specially designed to selectively target molecular 
pathways that are involved in the expression of 
aggressive phenotype in lung cancer cells. Hence, the 
exposure to toxic effects by surrounding normal cells is 
minimised. Novel cytotoxic agents for targeted therapy 
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include tyrosine kinase inhibitors (TKIs) directed against 
the EGFR. TKIs are from quinazolinamine class and 
inhibit the tyrosine kinase activity of the EGFR protein 
docking site by competing with ATP for the ATP-binding 
site (4).
 
Nevertheless, many patients inevitably develop acquired 
resistance and show disease progression. EGFR inhibitors 
can often reduce tumour size or even cause remission 
for several months or more. Unfortunately, these types 
of targeted therapy have been known to cause further 
mutations in the EGFR gene, such as T790M mutation 
which leads to treatment resistance (5, 6). Several large 
phase II clinical trial studies have demonstrated initial 
response to the TKIs including the reversible inhibitors, 
erlotinib and gefitinib (7, 8). Some of these patients 
show initial radiologically-assessed morphological 
response rates of  >60 % and improved progression free 
survival compared with treatment using conventional 
chemotherapy, only later to exhibit insensitivity to EGFR 
inhibitors (9, 10). 
 
Positron emission tomography/ computed tomography 
(PET/CT) can be especially helpful in addressing the 
issue of early detection of treatment resistance buy 
mapping the altered glucose metabolism of cancer cells. 
By using 18F-Fluorodeoxyglucose (18F-FDG), which 
is a glucose analogue, the in vivo cell metabolism can 
be imaged by the detection of intracellular photons 
emissions of trapped 18F-FDG molecules in cancer 
cells that have altered glucose metabolism but cannot 
enter the glycolysis pathway, thus getting trapped within 
cancer cells. As a matter of fact, normal physiology of 
cells is to undergo anaerobic glycolysis via the Krebs 
cycle in mitochondria. Conversely, in cancer cells a 
phenomena known as the Warburg effect, propagates 
increased glucose uptake into the cells allowing the cells 
to utilize glucose by a paradoxical ‘aerobic’ glycolysis 
driven by oncogenes thus producing lactic acid in the 
cytosol (11) which rely primarily on mitochondrial 
oxidative phosphorylation to generate the energy 
needed for cellular processes, most cancer cells instead 
rely on aerobic glycolysis, a phenomenon termed \” the 
Warburg effect. \” Aerobic glycolysis is an inefficient 
way to generate adenosine 5\u2032-triphosphate 
(ATP. Alternative theory also suggests that inhibition of 
mitochondrial anaerobic glycolysis impairs formation of 
reactive oxygen species and leads to reduced glutathione 
formation which hampers intracellular defence against 
damage and cell apoptosis, thus promoting cancer cell 
growth.
 
This shunting of glucose into alternative pathways 
are catalysed by the aberrant form of pyruvate kinase 
enzyme, M2-PK that increases production of the building 
blocks of cell formation and accelerates cell proliferation 
leading to proliferation of cancerous tumours (12). 
Furthermore, Studies show that absence of metabolic 
response to neoadjuvant chemotherapy correlates with 
poor pathologic response, and a favourable 18F-FDG 
PET/CT response appears to be associated with improved 
survival (10)combined-modality therapy, and early 
detection of recurrence. Here, we review the current 
literature on these aspects of PET in the management of 
NSCLC. FDG-PET, particularly integrated (18). 
 
Advanced, inoperable non-small cell lung cancers 
are generally treated with platinum based systemic 
chemotherapy. However, specific mutations in the 
epidermal growth factor receptor (EGFR) characterize 
a subgroup of patients that may be highly responsive 
to receptor inhibitor therapy. 18F-Fluorodeoxyglucose 
PET/CT imaging is considered the modality of choice 
to assess treatment response in NSCLC patients (13). 
Our objective was to assess the pattern of metabolic 
response as well as the outcome of inoperable non-
small-cell lung cancer patients that have undergone 
targeted treatment with epidermal growth factor (EGFR) 
inhibitors and followed up using 18F-FDG PET/CT. 
MATERIAL AND METHODS
A retrospective study was conducted based on data 
from inoperable, NSCLC patients on EGFR inhibitor 
treatment and re-staged with wholebody18F-FDG PET/
CT scan at the Centre for Diagnostic Nuclear Imaging, 
Universiti Putra Malaysia from January 2011 to June 
2014. All patients consented to the procedures and 
institutional ethical clerance was waived due to the 
nature of the study. We initially identified 6 patients, 
but one patient had to be dropped out of the study, as 
he did not have a comparison scan done at our centre. 
Thus, five patients (3 men; 2 women) were identified 
as fulfilling the study criteria. These patients had 
underwent serial contrast-enhanced CT (CECT) scans 
followed by 18F-Fluorodeoxyglucose positron emission 
tomography scans. All patients were kept fasted for the 
PET/CT examination and their fasting blood sugar (FBS) 
levels were checked prior to the scan.
 
The patients were administered with 18F-FDG dosage 
based on their body weight and the injected dose ranged 
from 7.89 to 11.25 mCi (mean 9.70 +/- 1.22). Patients 
were kept rested in a dim quiet room, which allowed 
for 18F-FDG uptake time, mean uptake time was 32.0 
+/- 4.5 minutes. All scans were performed following 
standard protocol using Siemens Truepoint Biograph 
‘TrueV®’ comprising Lutetium Oxyorthosilicate (LSO) 
scintillator crystal camera and 64 slice multidetected CT 
scanner. All images were analysed separately followed 
by combined analysis of attenuation-corrected fused 
PET/CT images on a Syngo Multi-Modality Workstation. 
Standardized uptake values (SUVmax), and anatomical 
tumour size were measured for the lesions detected and 
development of never sites of metastases were recorded. 
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Inclusion criteria for the study was that all the NSCLC 
patients who were initially treated with platinum-based 
chemotherapy and subsequently treated with EGFR 
inhibitors as a second line treatment and underwent 
baseline and follow up scans at our centre. They were 
non-selectively treated with EGFR inhibitors irrespective 
of their EGFR receptor status. We excluded cases that did 
not have a follow up scan at our centre for comparison 
and assessment of treatment response.
All patients then underwent PET/CT scan in a hybrid 
scanner and the images were analysed separately for 
CT images and fused PET/CT images and interpreted 
by consensus. Comparison was made among baseline 
and serial attenuation-corrected fused PET/CT images 
for all study patients throughout the course of their 
treatment. The lesion sizes on CT image alone and PET / 
CT images as well as the maximum standardized uptake 
values (SUVmax), were measured. The SUVmax values of 
target lesions at baseline were measured using a standard 
region of interest (ROI) measurement and compared 
with consecutive follow up PET/CT images. Presence 
of new metastatic lesions was also recorded.  Analysis 
based on PERCIST criteria was categorized into 4 levels 
ie. complete metabolic response – CMR – resolution of 
uptake in target lesion to below the mean uptake level of 
the liver, partial metabolic response – PMR – reduction 
of uptake of target lesion to approximately 30% of initial 
uptake, stable metabolic disease - SMD, and progressive 
metabolic disease – PMD – increased uptake of target 
lesion to approximately 30% or more compared to 
baseline uptake. Overall survival was calculated from 
date of diagnosis to date of death.
RESULTS 
We identified 5 patients diagnosed with Stage III and IV 
inoperable adenocarcinoma of the lung and treated with 
EGFR inhibitors. Three patients had three serial PET/CT 
scans, one patient had a baseline and comparison scan 
and another patient had 5 serial scans for comparison. 
Overall there were 16 PET/CT scans analysed for changes 
in SUVmax values in this study (Figure 1). Patients ranged 
from 53 – 61-years old (mean age: 57.4 +/- 2.9 years), 
the male: female ratio was 2:1. FBS levels of the patients 
ranged from 3.6 – 4.5 mmol/L. 
Figure 1: Line chart showing the changes in SUVmax values 
during serial follow up PET/CT scans of five non-small cell lung 
cancer patients A, B, C, D and E undergoing EGFR inhibitor 
treatment.
Figure 2: A 58-year old gentleman, diagnosed with inoperable NSCLC had been treated with 2nd line EGFR inhibitor therapy. (A): 
Initial PET/CT detected a left apical lung mass which showed avid FDG uptake, SUVmax 12.68g/mL. (B) Follow-up PET/Ct after 
several months of therapy detected reduction in SUVmax to 3.99g/mL, without a significant change in tumour size, demonstrating 
a partial metabolic response (PMR). 
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Based on Response Evaluation Criteria In Solid Tumors 
version 1.1 (RECIST 1.1) and PET Response Criteria in 
Solid Tumors (PERCIST), version 1.0; the largest diameter 
of target lesions at baseline was 6.0 cm and the smallest 
target lesion diameter was 3.0 cm. The SUVmax for the
main target lesions in the lung at baseline scan ranged 
from 2.5 g/mL – 12.68 g/mL.
Two patients showed initial partial metabolic response 
(PMR) as demonstrated by the green and orange lines in 
Figure 1; two had progressive metabolic disease (PMD) 
as demonstrated by the purple and red lines in Figure 1 
and one had complete metabolic response (CMR) after 
the initiation of treatment, which was demonstrated 
by the blue line in Figure 1. However, the patient with 
initial complete metabolic response (CMR) developed 
treatment resistance and PMD 5 months later. The 
patient had developed new small lung nodules and 
metastatic liver lesions that were inconspicuous on CT 
scan alone. Furthermore, one of the patients with initial 
PMR had good response to treatment and remained 
as stable metabolic disease (SMD). This patient had 
survived for more than 24 months after being treated 
with EGFR inhibitor therapy. However, the majority of 
patients eventually developed treatment resistance and 
succumbed to their illness. The median survival time 
from initiation of EGFR inhibitor treatment to death was 
17 months. 
Figure 4: (A) Baseline PET/CT revealed a 61-year old lady with Stage IV NSCLC to have multiple lung metastases and mediastinal 
lymphadenopathy (white arrow). (B) Follow-up PET/CT demonstrated remarkable response to treatment with resolution of the 
lymphadenopathy (black arrows) no abnormal FDG uptake throughout the body in keeping with complete metabolic response 
(CMR).  
Figure 3: A 62-year old lady with Stage IV NSCLC had 
a PET/CT scan done for re-staging (A): There was FDG 
hypermetabolism detected at segment VIII of the liver, SUVmax 
10.4g/mL (white arrow) (B) However, on axial plane whole 
body CT scan image in soft tissue window (W:250, L:50) at the 
level of the liver showed a vague hypodense focus (grey arrow) 
at the corresponding site in keeping with site of metastasis 
(inconspicuous on CT compared to PET). 
Two patients showed complete resolution of the 
main target lesion, however had persistent metastatic 
deposits. Subsequently, progressive metabolic disease 
was noted within one year of undergoing therapy. One 
of the patients who showed initial partial metabolic 
response subsequently had aggressive tumour 
recurrence within 5 months of treatment (primary 
tumour had size: 3.1cm,SUVmax :12.68g/mL reduced to 
size:1.66cm; SUVmax 3.99g/mL but subsequently there 
was increase in size to 1.97cm with new FDG avid 
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mediastinal lymphadenopathy , SUVmax :4.1 to 10.5g/
mL) in keeping with progressive metabolic disease 
(Figure 2). Nevertheless, PET/CT demonstrated good 
overall survival whereby, the average time of survival 
after EGFR inhibitor treatment was 20.0 months +/- 5.9 
months.
DISCUSSION
The management of non-small cell lung cancer often 
requires a multimodality approach to accurately 
diagnose, stage, and treat patients. PET/CT can be 
a non –invasive tool to study in vivo altered cell 
metabolism and aid in early detection of treatment 
response. By using the PERSIST criteria which takes 
into account the maximum standardized uptake values 
(SUVmax) in the liver to assess percentage of reduction 
of metabolic activity in the tumour as well as to assess 
the temporal changes of the dynamic SUV readings 
over the course of the treatment (14)the Response 
Evaluation Criteria in Solid Tumors (RECIST, clinicians 
are able to quantitatively monitor treatment response. 
Images can also be analysed according to RECIST 
criteria which is a set of published guidelines to assess 
cancer patients’ morphological response to treatment 
(15)many investigators, cooperative groups, industry 
and government authorities have adopted these criteria 
in the assessment of treatment outcomes. However, a 
Figure 5: (A): Right lower lobe lung mass on CECT (thick white arrow), (B) True metabolically active lesion on coronal PET/CT 
images (thin white arrow) however the signal uptake is seen slightly lower than the actual lesion due to misregistration artifact; 
(C) CECT scan showing stable disease (thick white arrow) as assessed using RECIST criteria due to similar diameter of the lesion 
in baseline and follow up scans (D) PET/CT is more accurate to pick up the increasing trend of SUVmax reading and wider area of 
FDG hypermetabolism (thin white arrow), therefore confirming progressive metabolic disease (PMD) by PERCIST criteria. 
number of questions and issues have arisen which have 
led to the development of a revised RECIST guideline 
(version 1.1. It includes definitions of the minimum size 
of measurable lesions, instructions about how many 
lesions to follow up and measure, and the use of a single 
dimensional measurement for evaluation of overall 
tumor burden (16).
 
Additionally, functional imaging which measures the 
altered glucose metabolism in cancer cells provides 
more accurate detection of disease progression 
compared to morphological assessment alone. For 
example, one of our subjects had small liver metastases 
(SUVmax 4 – 10 g/mL),  which was only picked up on 
PET/CT imaging (Figure 3). On further scrutinizing the 
CT scan images, an almost imperceptible focus of ill-
defined hypodensity was noted in the corresponding 
location. This demonstrates that PET/CT is sensitive to 
pick up lesions earlier by detecting the signals of altered 
metabolism as compared to the anatomical changes, 
which are usually detected at a later stage.
 
Furthermore, in our study, a subject with Stage IV 
adenocarcinoma lung showed complete metabolic 
response (Figure 4) and remission of her primary lesion, 
within 6 months post-treatment using EGFR inhibitors. 
This corresponds to other previous studies whereby 
non-smokers, women and patients of Asian origin have 
shown to benefit from EGFR inhibitor targeted treatment 
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for NSCLC (17). However, this patient developed new 
metastatic lesions 5 months later and died before her 
treatment regime could be altered. This illustrates that 
early detection of resistance is necessary to make a timely 
decision for change in treatment regime. Some studies 
have identified markedly reduced insulin-like growth 
factor (IGF)-binding protein 3, whereby administering 
insulin-like growth factor 1 receptor (IGFIR)-specific 
monoclonal antibody could prevent further cell growth 
and thus prevent tumor recurrence (18). 
Apart from improved lesion conspicuousness on PET/
CT, this modality also gives improved accuracy in 
detecting the truly metabolically active tumour size as 
illustrated in the case of a 68-year old gentleman, who 
had a right lower lobe adenocarcinoma and follow up 
scans were done to assess treatment response. Although 
there was no significant changes on the tumour size 
on CT scan as assessed by the RECIST criteria, there 
was significant increase in the SUVmax value and wider 
area of FDG hypermetabolism, indicating progressive 
metabolic disease (PMD) by PERCIST criteria (Figure 5). 
The discrepancy of the hypermetabolism area in Figure 
5B compared to correct uptake location in Figure 5D 
and the correct anatomical lesion location in Figure 5A 
is due to misregistration artefact that can sometimes be 
encountered in PET/CT imaging.
Moreover, our increased vigilance of these patients with 
PET/CT demonstrated good overall survival whereby, 
in this study the rate for best response being stable 
metabolic disease was 20% and the median survival 
time after EGFR inhibitor treatment was 17 months. This 
is comparable to previous studies that demonstrated 
patients with advanced NSCLC treated with EGFR 
inhibitors had median survival time of 19.6 months (19). 
Thus, PET/CT monitoring of EGFR inhibitor targeted 
therapy is recommended to be incorporated into 
management algorithms for patients progressing after 
standard chemotherapy.
Utility of PET/CT has clinical value in prognostication 
of NSCLC by diagnosing metabolically active disease 
which can be missed on conventional CT scans. PET/
CT is sensitive for early detection of tumour recurrence 
or disease progression. Therefore, accurate and timely 
staging and assessment of treatment response can be 
made for individualised NSCLC treatment. Therefore, 
we recommend patients who undergo targeted therapy 
to be followed up with PET/CT imaging for optimization 
of individualised treatment which and can help tailor 
chemotherapy treatment accordingly for patients with 
inoperable NSCLC. 
18F-FDG PET/CT is a sensitive imaging modality to 
detect disease remission or progression in non-small 
cell lung cancer. Although our study sample is small, 
it is quite reflective of our population. Nevertheless, we 
recommend larger sample population and prospective 
multicentre studies to help better understand altered 
glucose metabolism in NSCLC and for improved 
theragnostics.
CONCLUSIONS
Functional imaging utilizing 18F-Fluorodeoxyglucose 
PET/CT is able to assess metabolic treatment response of 
non-small cell lung cancers towards epidermal growth 
factor receptor inhibitor treatment. Application of PET/
CT illustrates that proper treatment monitoring with 
imaging in vivo altered glucose metabolism helps to 
improve survival and perhaps can determine a suitable 
time point to modify treatment regime in those who 
develop resistance. 
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